Literature DB >> 10662870

Economic burden of rheumatoid arthritis: a systematic review.

N J Cooper1.   

Abstract

OBJECTIVE: To summarize the state of knowledge with regard to the economic impact of rheumatoid arthritis (RA) and to highlight any weaknesses in the work conducted to date, so as to inform future RA cost-of-illness studies.
METHODS: Four computerized literature databases were searched to identify all the literature relevant to this review. Seven elements indicating a quality cost-of-illness study were established and used to appraise the literature identified critically. Where possible, costs reported by the different studies were converted to 1996 US dollars using the consumer price index for medical care.
RESULTS: Total average medical costs were reported to range from US$5720 (UK pound3575) to US$5822 (UK pound3638). Medication constituted between 8 and 24% of total medical costs, physician visits between 8 and 21%, and in-patient stays between 17 and 88%. The average number of days absent from work due to a person's RA was reported to range from 2.7 to 30 days/year.
CONCLUSION: The economic impact of RA in terms of cost was reported to be substantial by all studies reviewed. However, methodological problems meant that discrepancies in the average (per person) annual cost of RA existed across studies.

Entities:  

Mesh:

Year:  2000        PMID: 10662870     DOI: 10.1093/rheumatology/39.1.28

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  96 in total

1.  Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.

Authors:  Ramon Lyu; Marinella Govoni; Qian Ding; Christopher M Black; Sumesh Kachroo; Tao Fan; Augstina Ogbonnaya; Prina Donga; Jerrold Hill; Charles Makin
Journal:  Rheumatol Int       Date:  2015-08-28       Impact factor: 2.631

2.  Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.

Authors:  Andrew Hresko; Tzu-Chieh Lin; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-10       Impact factor: 4.794

3.  Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors:  Ashit Syngle; Sudeep Kaur; Inderjeet Verma; Tanya Syngle; Vijaita Syngle
Journal:  Clin Rheumatol       Date:  2017-06-21       Impact factor: 2.980

Review 4.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

5.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.

Authors:  Andreas Maetzel; Vibeke Strand; Peter Tugwell; George Wells; Claire Bombardier
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice.

Authors:  Manathip Osiri; Utis Deesomchok; Peter Tugwell
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

8.  Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.

Authors:  S M M Verstappen; J W G Jacobs; D M van der Heijde; Sj van der Linden; C M Verhoef; J W J Bijlsma; A Boonen
Journal:  Ann Rheum Dis       Date:  2006-12-15       Impact factor: 19.103

Review 9.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Michael P Lavalley
Journal:  Arthritis Rheum       Date:  2008-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.